Form 8-K

8-K — Armata Pharmaceuticals, Inc.

Accession: 0001104659-26-082850

Filed: 2026-07-13

Period: 2026-07-13

CIK: 0000921114

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — tm2620286d1_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (tm2620286d1_ex99-1.htm)

GRAPHIC (tm2620286d1_ex99-1img001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2620286d1_8k.htm · Sequence: 1

false

0000921114

2026-07-13

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND

EXCHANGE COMMISSION

Washington, DC

20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported):

July 13, 2026

ARMATA PHARMACEUTICALS, INC.

(Exact name of Registrant as specified in

its charter)

Washington

001-37544

91-1549568

(State or other jurisdiction

of incorporation or

organization)

(Commission File Number)

(IRS Employer Identification No.)

5005 McConnell Avenue

Los Angeles, California

90066

(Address of principal executive offices)

(Zip Code)

(310) 665-2928

(Registrant’s Telephone number)

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§

230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the

registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards

provided pursuant to Section 13(a) of the Exchange Act. ¨

Securities registered pursuant to Section 12(b) of

the Act:

Title

of Each Class

Trading

Symbol(s)

Name

of Each Exchange on Which Registered

Common Stock

ARMP

NYSE American

Item 7.01

Regulation FD Disclosure.

On July 13, 2026, Armata Pharmaceuticals, Inc.

(the “Company”) issued a press release announcing that it has received agreement from the U.S. Food and Drug Administration

(the “FDA”) on an Agreed Initial Pediatric Study Plan (“Agreed iPSP”), which establishes the agreed regulatory

framework for the future evaluation of AP-SA02 for the adjunct treatment of complicated Staphylococcus aureus bacteremia (“SAB”)

in pediatric patients. The full text of the press release issued in connection with this announcement is furnished as Exhibit 99.1 to

this Current Report on Form 8-K.

The information in this Item 7.01 and the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the

purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The

information in this Item 7.01 and the attached Exhibit 99.1 shall not be incorporated by reference into any registration statement or

other document pursuant to the Securities Act of 1933, as amended.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

No.

Description

99.1

Press Release, dated July 13, 2026.

104

Cover Page Interactive Data File (embedded within Inline XBRL document).

- 2 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf

by the undersigned hereunto duly authorized.

Date: July 13, 2026

Armata Pharmaceuticals, Inc.

By:

/s/ David House

Name:

David House

Title:

Senior Vice President, Finance and Principal Financial Officer

- 3 -

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2620286d1_ex99-1.htm · Sequence: 2

Exhibit

99.1

Armata

Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the

Treatment of Complicated Staphylococcus

aureus Bacteremia

Fulfills

important regulatory milestone for AP-SA02 on the path toward a future BLA and supports expansion into pediatric patients

LOS

ANGELES, Calif., July 13, 2026 - Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”),

a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for

the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has received agreement from

the U.S. Food and Drug Administration (the “FDA”) on an Agreed Initial Pediatric Study Plan (“Agreed iPSP”),

which establishes the agreed regulatory framework for the future evaluation of AP-SA02 for the adjunct treatment of complicated Staphylococcus

aureus bacteremia (“SAB”) in pediatric patients. Agreement with the FDA on an iPSP is a regulatory requirement that must

be met prior to submitting a Biologics License Application (“BLA”).

“Reaching

agreement with the FDA on our Agreed iPSP for AP-SA02 is an important regulatory milestone that reflects our commitment to addressing

the needs of both adult and pediatric patients with complicated SAB,” said Dr. Deborah Birx, Chief Executive Officer of Armata.

“Pediatric patients, especially very young premature babies and newborns, represent a particularly vulnerable population with limited

treatment options for serious S. aureus infections, and we are pleased to have an aligned, FDA-endorsed pediatric development

framework in place. This agreement positions us to work towards efficiently expanding development beyond adults while continuing to advance

AP-SA02 toward potential registration.”

The

Agreed iPSP outlines a proposed pediatric development program targeting patients up to 17 years of age with complicated SAB, the same

indication that Armata is pursuing in adults. Consistent with FDA requirements under the Pediatric Research Equity Act (PREA) and with

established FDA and European Medicines Agency regulatory frameworks, the FDA agreed that because the disease pathophysiology and treatment

response in SAB are consistent across all age groups, pediatric studies should be deferred until safety and efficacy data are generated

in adults in the planned Phase 3 program. Following completion of the adult Phase 3 study which is expected to initiate in the second

half of 2026, the proposed program will comprise a single, multicenter, open-label, pediatric study to assess safety, tolerability, and

clinical response outcomes. This strategy establishes a pathway for potential future expansion of AP-SA02 into the pediatric population

while prioritizing patient safety and efficient clinical development.

About

AP-SA02

Armata

is developing AP-SA02, a fixed multi-phage cocktail, for the adjunct treatment of complicated Staphylococcus aureus bacteremia

caused by methicillin-sensitive S. aureus (MSSA) or methicillin-resistant S. aureus (MRSA). AP-SA02 has received Qualified

Infectious Disease Product (QIDP), and Fast Track designations from the

FDA. The diSArm study (NCT05184764) was a Phase 1b/2a, multicenter, randomized, double-blind, placebo-controlled, multiple ascending

dose escalation study of the safety, tolerability, and efficacy of intravenous AP-SA02 in addition to best available antibiotic therapy

(“BAT”) compared to BAT alone (placebo) for the treatment of adults with complicated S. aureus bacteremia. Positive

results from the Phase 2a diSArm study were highlighted in a late-breaking oral presentation

at IDWeek 2025™ in October 2025. The Company plans to advance AP-SA02 into a Phase 3 superiority study in complicated S.

aureus bacteremia, anticipated to initiate in the second half of 2026.

About

Armata Pharmaceuticals, Inc.

Armata

is a late clinical-stage biotechnology company focused on the development of high-purity pathogen-specific bacteriophage therapeutics

for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology.

Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas

aeruginosa, S. aureus, and other important pathogens. Armata is committed to advancing phage therapy with drug development expertise

that spans bench to clinic including in-house phage-specific current Good Manufacturing Practices (“cGMP”) manufacturing

to support full commercialization.

Forward

Looking Statements

This

communication contains “forward-looking” statements as defined by the Private Securities Litigation Reform Act of 1995. These

statements relate to future events, results or to Armata’s future financial performance and involve known and unknown risks, uncertainties

and other factors which may cause Armata’s actual results, performance or events to be materially different from any future results,

performance or events expressed or implied by the forward-looking statements. In some cases, you can identify these statements by terms

such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,”

“may,” “plan,” “potential,” “predict,” “project,” “should,” “will,”

“would” or the negative of those terms, and similar expressions. These forward-looking statements reflect management’s

beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this communication and are

subject to risks and uncertainties including risks related to Armata’s development of bacteriophage-based therapies; Armata's planned

clinical trials; ability to staff and maintain its production facilities under fully compliant cGMP; ability to meet anticipated milestones

in the development and testing of the relevant product; ability to be a leader in the development of phage-based therapeutics; ability

to achieve its vision, including improvements through engineering and success of clinical trials; ability to successfully complete preclinical

and clinical development of, and obtain regulatory approval of its product candidates and commercialize any approved products on its

expected timeframes or at all; and Armata’s estimates regarding anticipated operating losses, capital requirements and needs for

additional funds. Additional risks and uncertainties relating to Armata and its business can be found under the caption “Risk Factors”

and elsewhere in Armata’s filings and reports with the U.S. Securities and Exchange Commission (the “SEC”), including

in Armata’s Annual Report on Form 10-K, filed with the SEC on March 25, 2026, and in its subsequent filings with the SEC.

Armata

expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained

herein to reflect any change in Armata’s expectations with regard thereto or any change in events, conditions or circumstances

on which any such statements are based.

Media

Contacts:

Armata:

Pierre

Kyme

ir@armatapharma.com

310-665-2928

Investor

Relations:

Joyce

Allaire

LifeSci

Advisors, LLC

jallaire@lifesciadvisors.com

212-915-2569

GRAPHIC

Filename: tm2620286d1_ex99-1img001.jpg · Sequence: 6

Binary file (3262 bytes)

Download tm2620286d1_ex99-1img001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Jul. 13, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jul. 13, 2026

Entity File Number

001-37544

Entity Registrant Name

ARMATA PHARMACEUTICALS, INC.

Entity Central Index Key

0000921114

Entity Tax Identification Number

91-1549568

Entity Incorporation, State or Country Code

Entity Address, Address Line One

5005 McConnell Avenue

Entity Address, City or Town

Los Angeles

Entity Address, State or Province

Entity Address, Postal Zip Code

90066

City Area Code

310

Local Phone Number

665-2928

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock

Trading Symbol

ARMP

Security Exchange Name

NYSEAMER

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration